p-medicine

Medicine is undergoing a revolution that is transforming the nature of healthcare from reactive to preventive. The changes are catalyzed by a new systems approach to disease which focuses on integrated diagnosis, treatment and prevention of disease in individuals. This will replace our current mode of medicine over the coming years with a personalized predictive treatment. While the goal is clear, the path is fraught with challenges. P-medicine brings together international leaders in their fields to create an infrastructure that will facilitate this translation from current practice to personalized medicine. In achieving this objective p-medicine has formulated a coherent, integrated work plan for the design, development, integration and validation of technologically challenging areas of today. Our emphasis is on formulating an open, modular framework of tools and services, so that p-medicine can be adopted gradually, including efficient secure sharing and handling of large personalized data sets, enabling demanding Virtual Physiological Human (VPH) multi-scale simulations (in silico oncology), building standards-compliant tools and models for VPH research, drawing on the VPH Toolkit and providing tools for large-scale, privacy-preserving data and literature mining, a key component of VPH research. We will ensure that privacy, non-discrimination, and access policies are aligned to maximize protection of and benefit to patients. The p-medicine tools and technologies will be validated within the concrete setting of advanced clinical research. Pilot cancer trials have been selected based on clear research objectives, emphasising the need to integrate multilevel datasets, in the domains of Wilms tumour, breast cancer and leukaemia. To sustain a self-supporting infrastructure realistic use cases will be built that will demonstrate tangible results for clinicians. The project is clinically driven and promotes the principle of open source and open standards.

For further information, please visit:
http://www.p-medicine.eu

Project co-ordinator:
Universität des Saarlandes

Partners:

  • CUSTODIX NV
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
  • SWISS INSTITUTE OF BIOINFORMATICS
  • ECANCERMEDICALSCIENCE AG
  • NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
  • INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS
  • A. PERSIDIS & SIA OE
  • GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER
  • HEINRICH-HEINE-UNIVERSITAET DUESSELDORF
  • UNIVERSIDAD POLITECNICA DE MADRID
  • IBM ISRAEL - SCIENCE AND TECHNOLOGY LTD
  • FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
  • FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
  • PHILIPS ELECTRONICS NEDERLAND B.V.
  • UNIVERSITY COLLEGE LONDON
  • EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
  • CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
  • INSTYTUT CHEMII BIOORGANICZNEJ PAN
  • ISTITUTO EUROPEO DI ONCOLOGIA SRL

Timetable: from 01/2011 to 01/2015

Total cost: € 18.480.000

EC funding: € 13.330.000

Programme Acronym: FP7-ICT

Subprogramme Area: ICT-2009.5.3 Virtual Physiological Human

Contract type: Collaborative project (generic)

Related news articles:

Most Popular Now

Siemens Healthineers Uses Artificial Int…

Siemens Healthineers introduces Ysio X.pree(1), the world's first intelligent X-ray system with integrated AI for optimizing the daily routine of image acquisition in radiography. To assist radiologists with the subsequent...

Digital Mental Health Interventions Have…

Treating anxiety and depression with digital mental health therapy has a significant and long-term benefit for recovery, new research amongst NHS service users suggests. The research was undertaken by SilverCloud...

Roche Improves Speed and Accuracy of Non…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The...

FDA Permits Marketing of First Game-Base…

The U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only...

Philips Announces Collaboration with Ame…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the...

Successful Debut for DMEA sparks

16 - 18 June 2020, Berlin, Germany. DMEA sparks opened, featuring a wide range of topics. Federal Minister of Health Jens Spahn kicked off events. In his interview he focused on...

Brazilian Scientists Develop COVID-19 Ac…

Researchers at São Paulo State University (UNESP) in Araçatuba, Brazil, have developed a computational tool that acts like a "COVID-19 accelerometer," plotting in real time the rate at which growth...

Member States Agree on an Interoperabili…

Member States, with the support of the Commission, have agreed on a set of technical specifications to ensure a safe exchange of information between national contact tracing apps based on...

Wearable Injectors and Connected Devices…

7 - 8 October 2020, London, United Kingdom. The global wearable devices market size is expected to reach a value of $62.82 billion USD by 2025 with time dependent delivery, improved...

Siemens Healthineers Offers Flexible Tel…

With its teamplay myCare Companion software, the company is bringing a new and flexible telemedicine solution to the market that enables remote care for patients with chronic diseases. The teamplay...

Andrea Fiumicelli Appointed as a CEO of …

Dedalus Group, leader in Europe and one of the world's leading players in clinical and healthcare information systems supporting clinical professionals and healthcare facilities thanks to a wide portfolio of...

First Virtual DMEA Comes to an End

16 - 18 June 2020, Berlin, Germany. More than 5,000 participants, over 100 Supporters and more than 500 contributions to the programme - these were the final figures after three days...